دورية أكاديمية
Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma.
| العنوان: | Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma. |
|---|---|
| المؤلفون: | Santos FM; Instituto Do Cancer Do Estado de Sao Paulo (ICESP), Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo-SP, Brazil. fernanda.maria@hc.fm.usp.br., Marin JFG; Nuclear Medicine Medical Investigation Laboratory LIM43, Hospital das Clinicas, FMUSP (HCFMUSP), Sao Paulo-SP, Brazil., Lima MS; Instituto Do Cancer Do Estado de Sao Paulo (ICESP), Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo-SP, Brazil.; Nuclear Medicine Medical Investigation Laboratory LIM43, Hospital das Clinicas, FMUSP (HCFMUSP), Sao Paulo-SP, Brazil., Silva-Junior WF; Instituto Do Cancer Do Estado de Sao Paulo (ICESP), Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo-SP, Brazil.; Division of Hematology and Cell Therapy, HCFMUSP, Sao Paulo-SP, Brazil., Alves LBO; Division of Hematology and Cell Therapy, HCFMUSP, Sao Paulo-SP, Brazil., Moreira FR; Division of Hematology and Cell Therapy, HCFMUSP, Sao Paulo-SP, Brazil., Velasques RD; Instituto Do Cancer Do Estado de Sao Paulo (ICESP), Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo-SP, Brazil.; Division of Hematology and Cell Therapy, HCFMUSP, Sao Paulo-SP, Brazil., Atanazio MJ; Instituto Do Cancer Do Estado de Sao Paulo (ICESP), Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo-SP, Brazil.; Division of Hematology and Cell Therapy, HCFMUSP, Sao Paulo-SP, Brazil., Maia ACA; Instituto Do Cancer Do Estado de Sao Paulo (ICESP), Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo-SP, Brazil.; Division of Hematology and Cell Therapy, HCFMUSP, Sao Paulo-SP, Brazil., Buchpiguel CA; Nuclear Medicine Medical Investigation Laboratory LIM43, Hospital das Clinicas, FMUSP (HCFMUSP), Sao Paulo-SP, Brazil., Buccheri V; Instituto Do Cancer Do Estado de Sao Paulo (ICESP), Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo-SP, Brazil.; Division of Hematology and Cell Therapy, HCFMUSP, Sao Paulo-SP, Brazil.; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Division of Hematology, HCFMUSP, Sao Paulo-SP, Brazil., Rocha V; Instituto Do Cancer Do Estado de Sao Paulo (ICESP), Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo-SP, Brazil.; Division of Hematology and Cell Therapy, HCFMUSP, Sao Paulo-SP, Brazil.; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Division of Hematology, HCFMUSP, Sao Paulo-SP, Brazil.; Department of Hematology, Churchill Hospital, NHS BT, Oxford University, Oxford, UK. |
| المصدر: | Annals of hematology [Ann Hematol] 2024 Jan; Vol. 103 (1), pp. 175-183. Date of Electronic Publication: 2023 Oct 05. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Berlin : Springer Verlag Original Publication: Berlin ; New York : Springer International, c1991- |
| مواضيع طبية MeSH: | Hodgkin Disease*/diagnostic imaging , Hodgkin Disease*/drug therapy, Humans ; Adult ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Fluorodeoxyglucose F18 ; Bleomycin ; Dacarbazine ; Doxorubicin ; Vinblastine ; Prognosis ; Positron Emission Tomography Computed Tomography ; Positron-Emission Tomography |
| مستخلص: | Currently, analysis of interim PET (iPET) according to the Deauville score (DS) is the most important predictive factor in Hodgkin lymphoma (HL); however, there is room for improvement in its prognostic power. This study aimed to evaluate the prognostic value of quantitative PET analysis (maximum standard uptake value [SUV (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| References: | Klimm B, Goergen H, Fuchs M et al (2013) Impact of risk factors on outcomes in early-stage Hodgkin’s lymphoma: An analysis of international staging definitions. Ann Oncol 24:3070–3076. https://doi.org/10.1093/annonc/mdt413. (PMID: 10.1093/annonc/mdt41324148816) Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. N Engl J Med 339:1506–1514. (PMID: 10.1056/NEJM1998111933921049819449) Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372:1598–1607. https://doi.org/10.1056/NEJMoa1408648. (PMID: 10.1056/NEJMoa140864825901426) André MPEE, Girinsky T, Federico M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35:1786–1796. https://doi.org/10.1200/JCO.2016.68.6394. (PMID: 10.1200/JCO.2016.68.639428291393) Trotman J, Fossa A, Federico M et al (2017) Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: Longer follow up confirms efficacy of de-escalation after a negative interim PET scan (CRUK/07/033). Hematol Oncol 35:65–67. https://doi.org/10.1002/hon.2437. (PMID: 10.1002/hon.2437) Johnson PW, Federico M, Fossa A et al (2015) Response-adapted therapy based on interim FDG-PET scans in advanced hodgkin lymphoma: First analysis of the safety of de-escalation and efficacy of escalation in the international rathl study (cruk/07/033). Hematol Oncol 33:102–103. https://doi.org/10.1002/hon.2227. (PMID: 10.1002/hon.2227) Gallamini A, Rossi A, Patti K et al (2017) Early chemotherapy intensification with escalated BEACOPP in advanced-stage Hodgkin lymphoma with a positive interim PET-CT after 2 ABVD cycles: Long-term results of the GITIL/FIL HD 0607 trial. Haematologica 102:145–146. Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752. https://doi.org/10.1200/JCO.2007.11.6525. (PMID: 10.1200/JCO.2007.11.652517646666) Zinzani PL, Broccoli A, Gioia DM et al (2016) Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study. J Clin Oncol 34:1376–1385. https://doi.org/10.1200/JCO.2015.63.0699. (PMID: 10.1200/JCO.2015.63.069926884559) Johnson P, Federico M, Kirkwood A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med 374:2419–2429. https://doi.org/10.1056/NEJMoa1510093. (PMID: 10.1056/NEJMoa1510093273329024961236) Stephens DM, Li H, Schoder H et al (2019) Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood 134:1238–1246. https://doi.org/10.1182/blood.2019000719. (PMID: 10.1182/blood.2019000719313319186788007) Cerci JJ, Pracchia LF, Linardi CCG et al (2010) 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 51:1337–1343. https://doi.org/10.2967/jnumed.109.073197. (PMID: 10.2967/jnumed.109.07319720720036) Straus DJ, Dlugosz-Danecka M, Alekseev S, et al (2019) Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study. J Clin Oncol 37:. https://doi.org/10.1200/JCO.2019.37.15_suppl.7532. Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R, Cottereau A, Versari A et al (2017) Prognostic value of baseline total metabolic tumor volume (TMTV) for patients with early stage Hodgkin lymphoma enrolled in the standard arm of the H10 (EORTC/LYSA/FIL) trial. Hematol Oncol 35:35–36. https://doi.org/10.1002/hon.2437. (PMID: 10.1002/hon.2437) Mettler J, Müller H, Voltin CA et al (2019) Metabolic tumor volume for response prediction in advanced-stage Hodgkin lymphoma. J Nucl Med 60:207–211. https://doi.org/10.2967/jnumed.118.210047. (PMID: 10.2967/jnumed.118.2100478833856) Pinochet P, Texte E, Stamatoullas-Bastard A, et al (2021) Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma. Sci Rep 11:. https://doi.org/10.1038/s41598-021-02734-w. Albano D, Mazzoletti A, Spallino M et al (2020) Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients. Ann Hematol 99:1321–1330. https://doi.org/10.1007/s00277-020-04039-w. (PMID: 10.1007/s00277-020-04039-w32333153) Barrington SF, Meignan M (2019) Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J Nucl Med 60:1096–1102. https://doi.org/10.2967/jnumed.119.227249. (PMID: 10.2967/jnumed.119.227249309549456681699) Cottereau AS, Versari A, Loft A et al (2016) Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial. Blood 128:184–184. https://doi.org/10.1182/blood.v128.22.184.184. (PMID: 10.1182/blood.v128.22.184.184) Rossi C, Kanoun S, Berriolo-Riedinger A et al (2014) Interim 18f-FDG PET Suvmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. J Nucl Med 55:569–573. https://doi.org/10.2967/jnumed.113.130609. (PMID: 10.2967/jnumed.113.13060924566003) Bonadonna G, Zucali R, Monfardini S et al (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252–259. https://doi.org/10.1002/1097-0142(197507)36:1%3c252::AID-CNCR2820360128%3e3.0.CO;2-7. (PMID: 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-754209) Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32:3059–3067. https://doi.org/10.1200/JCO.2013.54.8800. (PMID: 10.1200/JCO.2013.54.8800251137534979083) Engert A, Plütschow A, Eich HT et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652. https://doi.org/10.1056/NEJMoa1000067. (PMID: 10.1056/NEJMoa100006720818855) Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol 32:3048–3058. https://doi.org/10.1200/JCO.2013.53.5229. (PMID: 10.1200/JCO.2013.53.5229251137715015423) Boellaard R, Delgado-Bolton R, Oyen WJG et al (2014) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328–354. https://doi.org/10.1007/s00259-014-2961-x. (PMID: 10.1007/s00259-014-2961-x254522194315529) Contal C, O’Quigley J (1999) An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 30:253–270. https://doi.org/10.1016/S0167-9473(98)00096-6. (PMID: 10.1016/S0167-9473(98)00096-6) Lin LH, Hedayat A, Wu W (2012) Statistical tools for measuring agreement. Springer. (PMID: 10.1007/978-1-4614-0562-7) Biasoli I, Castro N, Delamain M et al (2018) Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry. Hematol Oncol 36:189–195. https://doi.org/10.1002/hon.2450. (PMID: 10.1002/hon.245028643458) Mahuad C, Victoria O, Laura K, Enriqueta M, Fernando W, Hernán GR et al (2022) Retrospective multicenter real-life study on the first-line treatment of classical Hodgkin lymphoma in Argentina. Clin Hematol Int 4:44–51. https://doi.org/10.1007/s44228-022-00008-4. (PMID: 10.1007/s44228-022-00008-4359502069358792) Rukavitsyn AA, Kurbanov SI, Rukavitsyn OA (2017) Prognostic and Differential Diagnostic Value of Standardized Uptake Volume (SUV) of Fluorodeoxyglucose in Patients with Hodgkin’s Lymphoma. Clin Oncohematol 10:182–186. https://doi.org/10.21320/2500-2139-2017-10-2-182-186. (PMID: 10.21320/2500-2139-2017-10-2-182-186) Angelopoulou MK, Mosa E, Pangalis GA et al (2017) The significance of PET/CT in the initial staging of hodgkin lymphoma: Experience outside clinical trials. Anticancer Res 37:5727–5736. https://doi.org/10.21873/anticanres.12011. (PMID: 10.21873/anticanres.1201128982893) Akhtari M, Milgrom SA, Pinnix CC et al (2018) Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood 131:84–94. https://doi.org/10.1182/blood-2017-04-773838. (PMID: 10.1182/blood-2017-04-773838290383395755043) Tseng D, Rachakonda L, Su Z, Advani R, Horning SHR et al (2012) Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin’s disease Tseng D. Radiat Oncol 7:1–7. (PMID: 10.1186/1748-717X-7-5) Kanoun S, Rossi C, Berriolo-Riedinger A et al (2014) Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 41:1735–1743. https://doi.org/10.1007/s00259-014-2783-x. (PMID: 10.1007/s00259-014-2783-x24811577) Casasnovas RO, Kanoun S, Tal I, Cottereau AS, Edeline V, Brice P et al (2016) Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial. J Clin Oncol 34:7509. https://doi.org/10.1200/JCO.2016.34.15_suppl.7509. (PMID: 10.1200/JCO.2016.34.15_suppl.7509) Song MK, Chung JS, Lee JJ et al (2013) Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma. Cancer Sci 104:1656–1661. https://doi.org/10.1111/cas.12282. (PMID: 10.1111/cas.12282240336667653520) Rigacci L, Puccini B, Zinzani PL et al (2015) The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). Am J Hematol 90:499–503. https://doi.org/10.1002/ajh.23994. (PMID: 10.1002/ajh.2399425720750) Straus DJ, Dlugosz-Danecka M, Connors JM et al (2020) Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. Blood 136:26–28. https://doi.org/10.1182/blood-2020-137089. (PMID: 10.1182/blood-2020-137089) Herrera AF, LeBlanc ML, Castellino SM et al (2023) SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). J Clin Oncol 41:LBA4–LBA4. https://doi.org/10.1200/JCO.2023.41.17\_suppl.LBA4. (PMID: 10.1200/JCO.2023.41.17\_suppl.LBA4) Hutchings M, Mikhaeel NG, Fields PA et al (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16:1160–1168. https://doi.org/10.1093/annonc/mdi200. (PMID: 10.1093/annonc/mdi20015939713) Zinzani PL, Rigacci L, Stefoni V et al (2012) Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging 39:4–12. https://doi.org/10.1007/s00259-011-1916-8. (PMID: 10.1007/s00259-011-1916-821894546) Gallamini AA, Barrington SF, Biggi A et al (2014) The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99:1107–1113. https://doi.org/10.3324/haematol.2013.103218. (PMID: 10.3324/haematol.2013.103218246588204040916) Zheng S, Gupta K, Goyal P et al (2023) Outcomes of patients with positive pnterim Positron Emission Tomography (PET) continuing ABVD in the clinical setting. Cancers (Basel) 15:1760. https://doi.org/10.3390/cancers15061760. (PMID: 10.3390/cancers1506176036980646) Yang S, Qiu L, Huang X et al (2020) The prognostic significance of ΔSUVmax assessed by PET/CT scan after 2 cycles of chemotherapy in patients with classic Hodgkin’s lymphoma. Ann Hematol 99:293–299. https://doi.org/10.1007/s00277-019-03892-8. (PMID: 10.1007/s00277-019-03892-831897678) |
| فهرسة مساهمة: | Keywords: Hodgkin lymphoma; Metabolic tumor volume; Positron emission tomography; Total lesion glycolysis |
| المشرفين على المادة: | 0Z5B2CJX4D (Fluorodeoxyglucose F18) 11056-06-7 (Bleomycin) 7GR28W0FJI (Dacarbazine) 80168379AG (Doxorubicin) 5V9KLZ54CY (Vinblastine) |
| تواريخ الأحداث: | Date Created: 20231005 Date Completed: 20240103 Latest Revision: 20240103 |
| رمز التحديث: | 20240103 |
| DOI: | 10.1007/s00277-023-05461-6 |
| PMID: | 37796339 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-0584 |
|---|---|
| DOI: | 10.1007/s00277-023-05461-6 |